|
|
|
|
Direct Cost |
Indirect Cost |
|
| 1F32CA220990-01 |
Passive and active targeting of unnatural chemokine fusions for cancer immunotherapies |
BOSTON CHILDREN'S HOSPITAL |
NCI |
$61,174 |
|
$61,174 |
| 1F32DK115081-01A1 |
Development of a lineage-specific gene therapy approach in a mouse model of very early-onset inflammatory bowel disease |
BOSTON CHILDREN'S HOSPITAL |
NIDDK |
$59,038 |
|
$59,038 |
| 1F32DK116429-01A1 |
The functions of initial and expanding lipid droplets in NAFLD |
BOSTON CHILDREN'S HOSPITAL |
NIDDK |
$69,586 |
|
$69,586 |
| 1F32EY029556-01 |
The Role of Cortical Feedback in the Developmental Organization of the Thalamus |
BOSTON CHILDREN'S HOSPITAL |
NEI |
$59,038 |
|
$59,038 |
| 1K01DA045294-01A1 |
Role of Dopamine Neuron-Specific Gene Enhancers in Cocaine Relapse |
BOSTON CHILDREN'S HOSPITAL |
NIDA |
$169,304 |
$13,544 |
$182,848 |
| 1K01DK116932-01 |
Delivering contextualizing population data to patients to motivate health care transition preparation |
BOSTON CHILDREN'S HOSPITAL |
NIDDK |
$145,819 |
$11,144 |
$156,963 |
| 1K01HL143111-01 |
Mechanoregulation of the Leukocyte Specific Integrin LFA-1 by the Actin Cytoskeleton |
BOSTON CHILDREN'S HOSPITAL |
NHLBI |
$160,733 |
$12,859 |
$173,592 |
| 1K08AR073339-01 |
The Reprogramming of Regulatory T cells to a Th17 Phenotype in Systemic Juvenile Idiopathic Arthritis |
BOSTON CHILDREN'S HOSPITAL |
NIAMS |
$155,542 |
$12,443 |
$167,985 |
| 1K08HL140197-01A1 |
Novel molecular therapies for CPVT |
BOSTON CHILDREN'S HOSPITAL |
NHLBI |
$157,560 |
$12,605 |
$170,165 |
| 1K23DK119546-01 |
Effects of dietary carbohydrate on postprandial metabolism, brain function and type 1 diabetes control |
BOSTON CHILDREN'S HOSPITAL |
NIDDK |
$180,367 |
$13,644 |
$194,011 |
| 1K23NS107646-01 |
Diagnosis and genotype-phenotype correlations in early life epilepsy and CDKL5 disorder |
BOSTON CHILDREN'S HOSPITAL |
NINDS |
$183,560 |
$13,747 |
$197,307 |
| 1K99AI130258-01A1 |
Regulation of antiviral immunity at barrier surfaces by interleukin-1 family cytokines |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$120,813 |
$9,665 |
$130,478 |
| 1K99AI137300-01 |
Structural and Mechanistic Elucidation of NAIP/NLRC4 Inflammasomes in Innate Immunity |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$124,090 |
$9,927 |
$134,017 |
| 1K99DC016644-01A1 |
Trans-Tympanic Drug Delivery for Treatment and Prophylaxis of Otitis Media |
BOSTON CHILDREN'S HOSPITAL |
NIDCD |
$124,372 |
$9,950 |
$134,322 |
| 1K99DE028360-01 |
Defining the generators of spontaneous trigeminal pain |
BOSTON CHILDREN'S HOSPITAL |
NIDCR |
$94,268 |
$7,541 |
$101,809 |
| 1K99HD094900-01 |
Understand new genomic imprinting mechanisms by epigenome editing and Drop-seq |
BOSTON CHILDREN'S HOSPITAL |
NICHD |
$124,098 |
$9,928 |
$134,026 |
| 1R01AI128976-01A1 |
Mechanisms of Combined Immunodeficiency due to DOCK8 Deficiency |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$200,000 |
$154,000 |
$354,000 |
| 1R01AI130307-01A1 |
FDC regulation of self-reactive B cells |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$300,000 |
$231,000 |
$531,000 |
| 1R01AI135720-01 |
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$1,137,732 |
$301,369 |
$1,439,101 |
| 1R01AI136503-01 |
Role of DEPTOR in T Cell Activation and Alloimmunity |
BOSTON CHILDREN'S HOSPITAL |
NIAID |
$250,000 |
$192,500 |
$442,500 |